ALLERGY THERAPEUTICS PLC

Report Publication Announcement • Oct 23, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1587V

Allergy Therapeutics PLC

23 October 2014

23 October 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Annual Report and Accounts

Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company, announces that the Annual Report and Accounts of the Company for the year ended 30 June 2014 and Notice of Annual General Meeting have been posted to shareholders.

The Annual Report and Accounts and Notice of the Annual General Meeting are available on the Company's website in the Investor Relations section. They can be located at http://www.allergytherapeutics.com/Reports%20and%20Presentations%20Sub.aspx for the Annual Report and Accounts and http://www.allergytherapeutics.com/AGM.aspx for the Notice of the Meeting.

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSBSBDGLBDBGSX